Synthesis, optical and electrochemical properties of a series of push-pull dyes based on the 2-(3-cyano-4,5,5-trimethylfuran-2(5H)-ylidene)malononitrile (TCF) acceptor
A series of chromophores was designed and synthesized using 2-(3-cyano-4,5,5-trimethylfuran-2 (5H) -ylidene) malononitrile (TCF) as the electron acceptor and differing from each other by the use of thirteen different electron donors. The different dyes were characterized for their optical and electrochemical properties and theoretical calculations were also carried out to support the experimental results
5,7-tetranitrofluorene (TNF) as the electronacceptor have been designed and prepared in a one-step synthesis. By modifying the electrondonor, optical properties of the dyes could be efficiently tuned and an absorption ranging between 450 nm and 700 nm could be determined by UV-visible absorption spectroscopy. To get a deeper insight into the optical properties, solvatochromism of the fourteen dyes
COMPOUNDS AND METHODS FOR PREPARATION OF DIARYLPROPANES
申请人:Nandy Sandip K.
公开号:US20120245393A1
公开(公告)日:2012-09-27
Compounds of structure (I):
including stereoisomers, tautomers and salts thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, X, Y and Z are as defined herein. Such compounds are useful for the preparation of diarylpropane compounds. Methods for the preparation of compounds of structure (I) are also disclosed, as are methods employing compounds of structure (I) for the preparation of diarylpropanes.
Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia
申请人:JAEHNE Gerhard
公开号:US20080274947A1
公开(公告)日:2008-11-06
The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistance and the like comprising diphenylazetidinones compounds which have an additional hydroxy function in the 2″ position and their salts. The invention therefore relates to compounds of formula I:
in which the meanings R1, R2, R3, R4, R5, R6 are defined herein.
An agent for increasing the sugar-transporting capacity and an agent for preventing and/or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which contains a lactam compound or a pharmaceutically acceptable salt thereof as the active ingredient.